Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
ASP Isotopes (ASPI): Assessing the Path to the $13 Analyst Target

ASP Isotopes (ASPI): Assessing the Path to the $13 Analyst Target

Key Takeaways

  • The central target used here is $13, the arithmetic mean of three verified analyst price targets — Canaccord Genuity ($11), Cantor Fitzgerald ($13), and Lucid Capital ($15) — giving a low-to-high range of $11 to $15.
  • With shares near $1.23, the stock would need to rise roughly 950% to reach $13, a very large move for a development-stage company.
  • ASP Isotopes is not yet profitable: trailing-twelve-month revenue was about $31 million against a net loss well over $100 million, so the targets rest on future commercialization rather than current earnings.
  • The strongest supporting factors are proprietary isotope-enrichment technology, helium and nuclear-fuel growth, and management's long-term EBITDA (earnings before interest, taxes, depreciation, and amortization) ambitions.
  • The biggest risks are heavy cash burn, share dilution, extreme volatility, and price targets that may not have fully caught up with the stock's steep decline.
  • Readers can track Major News, Today's Price Move, the Forecast, and Earnings for ASP Isotopes on dedicated pages.
  • For automated, AI-driven market scanning, explore Trending AI Robots to discover signals across thousands of stocks and ETFs.

What the Analysts Are Saying

ASP Isotopes Inc. (ASPI) is a Nasdaq-listed, development-stage advanced-materials company that enriches isotopes used in nuclear fuel, healthcare, quantum computing, and other industries. It is covered by a small pool of analysts. Three verifiable, current price targets were reviewed: Canaccord Genuity at $11 (maintained September 16, 2026), Cantor Fitzgerald at $13 (initiated December 4, 2025 and reaffirmed in January 2026), and Lucid Capital at $15 (initiated October 27, 2025).

The simple average of these three targets is $13, matching the rounded central target used in the headline. The range is relatively narrow in percentage terms for such a volatile stock — $11 to $15 — but all three targets sit far above the current share price. Notably, these figures were largely set before, or early in, the stock's sharp 2026 selloff, and data providers have flagged that price targets "may not have had time to catch up" with the decline. The view is uniformly bullish (Strong Buy), but with only three analysts the sample is thin and should be treated with caution. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

The shares closed near $1.23 in mid-November 2026, down more than 80% from their 52-week high above $8 and not far from their 52-week low. Reaching $13 would therefore require a gain of roughly 950%, an extraordinarily large move by any standard. There is no near-term, step-by-step path visible in current fundamentals; any move of this magnitude would require a fundamental re-rating driven by sustained commercialization, not a single catalyst.

The company is pre-profit: trailing-twelve-month revenue of about $31 million contrasts with a net loss exceeding $100 million and negative EPS (earnings per share) around -$1.50. Investors should understand that the $13 target represents a long-run, execution-dependent outcome rather than a reflection of today's income statement.

What Could Support a Move Toward the Target

ASP Isotopes owns proprietary enrichment processes — the Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE) — aimed at structurally short, high-value isotope markets. Recent developments include stable liquid-helium production at the Renergen Virginia Gas Project in South Africa (announced October 2026) and a heads-of-agreement framework for a South African high-assay low-enriched uranium (HALEU) joint venture. The company also holds cash (roughly $200 million) to fund scaling, and management has outlined an ambition of $300 million to $700 million in EBITDA by 2031. Continued helium ramp-up, nuclear-fuel demand, radiopharmaceutical acquisitions, and successful execution on isotope shipment volumes could all support a higher valuation. From what I see, the technology edge remains a key differentiator worth monitoring.

What Could Prevent the Target From Being Reached

The principal obstacle is the gap between ambition and current financial reality. Heavy research and development spending and operating losses continue, and the share count has risen sharply (over 60% year over year), diluting existing holders. The company missed consensus EPS in its most recent reported quarter, and its beta of roughly 3.8 signals volatility far above the broader market. Targets set when the stock traded higher may overstate achievable upside if commercialization timelines slip, if helium and HALEU revenue scale more slowly than expected, or if dilution and cash burn persist. A move back toward $13 would also require clearing a very wide psychological and valuation gap.

Technical Levels and Market Structure

The stock trades near its 52-week low, with its 50-day moving average around $2.41 — itself well below the analyst targets. The $1.00 level is a key psychological support, while prior trading ranges near $2.50–$4.00 represent potential resistance zones on any recovery. Long-term trend structure remains firmly downward, meaning any meaningful advance would first need to establish a base and reclaim these lower levels before the $13 objective becomes even remotely relevant. I’m watching this closely for any signs of stabilization.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though firms do not always disclose an exact timeframe. For ASP Isotopes, the $13 figure should be read as a medium- to long-term aspiration tied to execution rather than a near-term forecast. Investors should monitor quarterly results and guidance, helium production and sales volumes, progress on the HALEU joint venture, radiopharmaceutical deals, analyst revisions and target changes, share issuance, and cash position. Any update to the company's 2031 EBITDA roadmap would also be directly relevant to the $13 objective.

Final Assessment

Can ASP Isotopes reach $13? The $13 figure is the arithmetic mean of three verified analyst targets ranging from $11 to $15 — a uniform Strong Buy view, but one built on a small sample and set partly before the stock's collapse. From roughly $1.23, the required gain is about 950%, an extremely large move that would demand a complete transformation in execution: profitable helium and isotope commercialization, nuclear-fuel scale-up, and disciplined control of dilution and losses. The technology story and long-term EBITDA ambition are real, but the gap to profitability is equally real. The $13 target should be understood as a bullish, long-horizon aspiration rather than a near-term expectation, and it carries no guarantee.

Using Tickeron’s AI Daily Buy/Sell Signals

For traders seeking a data-driven edge, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. The tool is designed to help investors discover new opportunities, keep tabs on existing positions, and spot changing trends more efficiently than manual screening. I rely on this resource regularly to cross-check ideas like the one discussed here and to stay on top of broader market shifts without spending hours on manual reviews. Explore the AI Daily Buy/Sell Signals to see how it can support your research process.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ASPI

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for ASPI turns negative, indicating new downward trend

ASPI saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 66 similar instances where the indicator turned negative. In 59 of the 66 cases, the stock moved further down in the following days. The odds of a decline are at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for ASPI turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 31 similar instances when the indicator turned negative. In 27 of the 31 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASPI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for ASPI entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +24.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASPI advanced for three days, in 198 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

ASPI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.202) is normal, around the industry mean (2.284). P/E Ratio (-1.634) is within average values for comparable stocks, (-17.137). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.548). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (11.062) is also within normal values, averaging (48.960).

The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. ASPI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASPI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.

Notable companies

The most notable companies in this group are DuPont de Nemours (NYSE:DD), Chemours Company (The) (NYSE:CC).

Industry description

The specialty chemicals sector includes companies that produce chemicals and industrial gases, which are of relatively high-value, often made to customer specifications. Examples of specialty chemicals are electronic chemicals, industrial gases, coatings, adhesives and sealants, industrial and institutional cleaning chemicals. The products are often valued on the basis of their purposes/performances rather than for their composition. Linde Plc, Ecolab Inc., Air Products and Chemicals, Inc., and Dow, Inc. are some of the largest companies making specialty chemicals.

Market Cap

The average market capitalization across the Chemicals: Specialty Industry is 11.6B. The market cap for tickers in the group ranges from 50 to 237.52B. LIN holds the highest valuation in this group at 237.52B. The lowest valued company is JSCPY at 50.

High and low price notable news

The average weekly price growth across all stocks in the Chemicals: Specialty Industry was -8%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -16%. FF experienced the highest price growth at 8%, while ASPI experienced the biggest fall at -37%.

Volume

The average weekly volume growth across all stocks in the Chemicals: Specialty Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was -7% and the average quarterly volume growth was -5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 50
Price Growth Rating: 59
SMR Rating: 78
Profit Risk Rating: 84
Seasonality Score: 0 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ChemicalsSpecialty

Industry
N/A
Address
2200 Ross Avenue
Phone
+1 214 432-8219
Employees
271
Web
https://www.aspisotopes.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.